Open AccessDEVELOPMENT AND METHODOLOGY FOR THE ESTIMATION OF ATENOLOL AND VALSARTAN IN PHARMACEUTICALS
Author(s) -
K. Ye. Peleshok,
Liliya Logoyda,
Olha Poliak
Publication year - 2020
Publication title -
zdobutki klìnìčnoï ì eksperimentalʹnoï medicini
Language(s) - English
Resource type - Journals
eISSN - 2415-8836
pISSN - 1811-2471
DOI - 10.11603/1811-2471.2020.v.i1.11066
Subject(s) - atenolol , valsartan , medicine , pharmacology , chromatography , blood pressure , chemistry
According to the appropriate protocols for the treatment of hypertension are often used antihypertensive drugs of the 5 main classes – first-line drugs, which when used in equivalent doses contribute to the reduction of blood pressure and significantly reduce the risk of cardiovascular complications. Quite often, doctors prescribe two/three medicines at a time. Therefore, the creation of fixed combinations antihypertensive action in the form of solid dosage forms is an urgent task of modern pharmacy.
The aim of the study – to improve to more rapid, simple, selective, less expensive methods TLC analysis of simultaneous determination of atenolol and valsartan in pharmaceuticals.
Methods. The present study assessed mobile phases of atenolol and valsartan for TLC.
Results and Discussion. Method of simultaneous identification of atenolol and valsartan by TLC has been developed. We have established that the most optimal Rf observed using mobile phases for simultaneous determination of atenolol and valsartan: n-butanol-acetic acid-water (40:10:20). We have explored the validation characteristics – specificity and suitability of the chromatographic system that met, the eligibility criteria established by the SPU.
Conclusion. We have developed chromatographic method for simultaneous determination of atenolol and valsartan. Prospects for future research will be aimed at developing analytical methods of analysis.